Latest New Drug Applications
شكل دارو:قرص
تاریخ تصویب : May 6, 2010
شرکت : Bayer HealthCare Pharmaceuticals Inc
نام دارو: کپسایسین ( Qutenza (capsaicin
شكل دارو: Transdermal patch
تاریخ تصویب : 2009 نوامبر 16
شرکت : NeurogesX ، Inc.
درمان : درد Postherpetic کپسایسین برای مدیریت درد به علت درد postherpetic بكار ميرود
نام دارو: ( Lystead (tranexamic acid
شكل دارو: قرص
تاریخ تصویب : 2009 نوامبر 13
شرکت : : Xanodyne Pharmaceuticals, Inc.
درمان: Menorrhagia Lysteda (اسید tranexamic) عامل antifibrinolytic برای درمان زنان مبتلا به menorrhagia است ، سنگین و خونریزی قاعدگی (HMB) ، و علائم همراه آن است.
نام دارو: Istodax
شكل دارو: for Injection
تاریخ تصویب : 2009 نوامبر 5
شرکت : داروسازی Gloucester
درمان: Cutaneous T-cell Lymphoma
Istodax (romidepsin) a histone deacetylase (HDAC) inhibitor indicated the treatment of cutaneous T-cell lymphoma.
نام دارو: دیکلوفناک سدیم ( Pennsaid (diclofenac sodium
شكل دارو: Topical Solution محلول موضعي
تاریخ تصویب : 2009 نوامبر 4
شرکت : Nuvo Research Inc.
درمان: NSAID موضعي برای درمان علائم و نشانه ها از استئوآرتریت از زانو.
نام دارو: Arzerra ofatumumab
شكل دارو: Injection
تاریخ تصویب : 2009 اکتبر 26
شرکت : گلاکسو اسمیت کلاین GlaxoSmithKline
درمان: : سرطان خون مزمن Lymphocytic
آنتی بادی مونوکلونال نشان داد برای درمان بیماران مبتلا به سرطان خون مزمن lymphocytic.
نام دارو: Votrient pazopanib
شكل دارو: قرص
تاریخ تصویب : 2009 اکتبر 19
شرکت : گلاکسو اسمیت کلاین GlaxoSmithKline
درمان: کارسینوم سلول کلیوی : یک مهاركننده برای درمان بیماران مبتلا به سرطان پیشرفته سلول های کلیوی
نام دارو: Twynsta(telmisartan and amlodipine)
شكل دارو: قرص
تاریخ تصویب : 2009 اکتبر 16
شرکت : : Boehringer Ingelheim
درمان: : فشار خون بالا :تركيبي ازمهاركننده گيرنده آنژيوتانسيون IIو كلسيم بلوكر
نام دارو: Cervarix
شكل دارو: تزریقي ،واکسن نوترکیب
تاریخ تصویب : 2009 اکتبر 16
شرکت : گلاکسو اسمیت کلاین GlaxoSmithKline
درمان:پروفيلاكسي ویروس پاپیلومای انسانی(ویروس پاپیلومای انسانی دارای دو تايپ 16 و 18 مي باشد بعنوان يك واكسن پيشگيرانه در سرطان گردن رحم در موارد زير در دختران وزنان جوان بكار ميرود:
prevention of cervical pre-cancers*
*cancer associated with oncogenic human papillomavirus
نام دارو: Berinert
شكل دارو: تزریقي
تاریخ تصویب : 2009 اکتبر 9
شرکت : CSL بهرینگ
درمان: آنژیوادم مهار کننده C1 – استراز انسان است كه مشتق از پلاسما C1 استراز بازدارنده مي باشدكه برای درمان حملات حاد در ناحیه شکم و یا فک و صورت و آنژیوادم (HAE) ارثی در بیماران بزرگسال و نوجوان بكار ميرود.
نام دارو: Stelara ustekinumab
شكل دارو: تزریقي
تاریخ تصویب : 2009 سپتامبر 25
شرکت : : Centocor Ortho Biotech Inc.
درمان: : پسوریازیس– آنتی بادی مونوکلونال انسانی برای درمان است پلاک پسوریازیس متوسط تا شدید.
نام دارو: Folotyn pralatrexate
شكل دارو: تزریقي
تاریخ تصویب : 2009 سپتامبر 24
شرکت : Allos Therapeutics, Inc.
درمان: محیطی لنفوم Ŧ سلول– آنالوگ مهار کننده متابولیسم فولات برای درمان بیماران مبتلا به Ŧ مبتلا به عود و یا لنفوم سلول محیطی (PTCL) می باشد.
Krystexxa (pegloticase) – formerly Puricase
Company: Savient Pharmaceuticals, Inc.
Treatment for: Gout
Krystexxa (pegloticase) is a bio-uricolytic agent in late-stage development for treatment-failure gout to control hyperuricemia and to manage the signs and symptoms of gout.
Ciltyri (eplivanserin)
Company: Sanofi-aventis
Treatment for: Insomnia
Ciltyri (eplivanserin) is a serotonin type 2 A receptor antagonist under review as a potential treatment for patients with chronic insomnia characterized by difficulties with sleep maintenance.
Xiaflex (collagenase clostridium histolyticum)
Company: BioSpecifics Technologies Corp.
Treatment for: Dupuytren’s Disease
Xiaflex (collagenase clostridium histolyticum) is a collagenase product in development for the treatment of Dupuytren’s disease.
Surfaxin (lucinactant)
Company: Discovery Laboratories, Inc.
Treatment for: Respiratory Distress Syndrome
Surfaxin, an engineered version of natural human lung surfactant, represents a potential alternative to the commercially available animal-derived surfactants used for the prevention of Respiratory Distress Syndrome in premature infants.
Belotero Balance (hyaluronic acid)
Company: Merz Pharmaceuticals, LLC
Treatment for: Glabellar Lines
Belotero Balance (hyaluronic acid) is a monophasic gel dermal filler in development for the correction of moderate to severe wrinkles and folds.
trabectedin
Company: Ortho Biotech Products, L.P.
Treatment for: Ovarian Cancer
Trabectedin is an investigational cytotoxic antitumor agent used in combination with Doxil (doxorubicin HCl liposome injection) for the treatment of women with relapsed ovarian cancer.
Cervarix (human papillomavirus vaccine, AS04 adjuvant-adsorbed)
Company: GlaxoSmithKline
Treatment for: Human Papillomavirus Prophylaxis
Cervarix (human papillomavirus vaccine, AS04 adjuvant-adsorbed) is a preventative cervical cancer vaccine under review for the prevention of cervical cancer and cervical pre-cancer related to human papillomavirus types 16 and 18.
Omapro (omacetaxine mepesuccinate)
Company: ChemGenex Pharmaceuticals
Treatment for: Chronic Myelogenous Leukemia
Omacetaxine mepesuccinate, a first-in-class small molecule which induces apoptosis by inhibition of protein synthesis is a new drug in development for the treatment of imatinib-resistant chronic myeloid leukemia (CML) patients with the T315I mutation.
NasalFent (fentanyl) Nasal Spray
Company: Archimedes Pharma
Treatment for: Pain
NasalFent (fentanyl citrate) is an opiate analgesic nasal spray in development to provide rapid and convenient relief for breakthrough cancer pain.
Pixantrone
Company: Cell Therapeutics, Inc.
Treatment for: non-Hodgkin’s Lymphoma
Pixantrone (BBR 2778) is a novel major groove binder with an aza-anthracenedione molecular structure in development to treat relapsed or refractory aggressive non-Hodgkin’s lymphoma (NHL).
SYR-322/Actos (alogliptin and pioglitazone) Tablets
Company: Takeda Pharmaceutical Company Limited
Treatment for: Diabetes Mellitus Type II
Alogliptin (SYR-322) and Actos (pioglitazone HCl) (“alogliptin/Actos”) is an investigational fixed-dose combination of a DPP-4 inhibitor and a thiazolidinedione for the treatment of type 2 diabetes.
Acurox (oxycodone hydrochloride and niacin)
Company: Acura Pharmaceuticals, Inc.
Treatment for: Pain
Acurox (oxycodone hydrochloride and niacin) is an oral immediate release narcotic analgesic in development for the relief of moderate to severe pain. Acurox is designed to deter common methods of opioid misuse and abuse.
belatacept
Company: Bristol-Myers Squibb Company
Treatment for: Organ Transplant — Rejection Prophylaxis
Belatacept is a fusion protein in development to help prevent graft rejection and maintain kidney function following renal transplantation.
Folotyn (pralatrexate)
Company: Allos Therapeutics, Inc.
Treatment for: non-Hodgkin’s Lymphoma
Folotyn (pralatrexate) is a a small molecule chemotherapeutic agent in development for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Nebido (testosterone undecanoate) Intramuscular Injection
Company: Endo Pharmaceuticals
Treatment for: Hypogonadism — Male
Nebido is a long-acting depot preparation of testosterone undecanoate, developed for the treatment of male hypogonadism. Nebido is expected to be the first three-month testosterone preparation available in the U.S.
ceftobiprole
Company: Johnson Pharmaceutical Research & Development, L.L.C.
Treatment for: Skin and Structure Infection
Ceftobiprole is an investigational antibiotic, for the treatment of complicated skin and skin structure infections (cSSSI), including diabetic foot infections, in adults.
romidepsin
Company: Gloucester Pharmaceuticals
Treatment for: Cutaneous T-cell Lymphoma
Romidepsin belongs to a new class of cancer drugs known as histone deacetylase (HDAC) inhibitors. Romidepsin is under review for the treatment of cutaneous T-cell lymphoma (CTCL) and is in clinical trials for the treatment of peripheral T-cell lymphoma (PTCL) and multiple myeloma.
velaglucerase alfa
Company: Shire plc
Treatment for: Gaucher Disease
Velaglucerase alfa is an enzyme replacement therapy in development for the treatment of Gaucher Disease.
Onrigin (laromustine) Injection
Company: Vion Pharmaceuticals, Inc.
Treatment for: Acute Myeloid Leukemia
Onrigin (laromustine), formerly known as Cloretazine (VNP40101M), is a novel alkylating agent in development for remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML).
Hexvix (hexaminolevulinate)
Company: PhotoCure ASA
Treatment for: Diagnostic
Hexvix (hexaminolevulinate) is a diagnostic agent in development for the detection of papillary bladder cancer using fluorescence cystoscopy
great post as usual!